ROCHE – Group report and key figures

WHAT IS THE GROUPS' FINANCIAL SITUATION ?

The financial indicators presented in this report include: consolidated revenue, consolidated EBIT and EBIT ratio, consolidated net profit and net profit rate, R&D expenditure and ratio, sales by segment and by region, profitability, liquidity and solvency ratios, free cash flow and capital expenditure.

WHAT ARE THE GROUP'S STRATEGIC PRIORITIES ?

Focus R&D pipeline on molecules with best-in-class potential

Extend portfolio into new treatment areas

Accelerate healthcare digitalisation

WHAT ARE THE GROUP'S STRENGTHS AND WEAKNESSES ?

Through a SWOT analysis, this report also provides an overview of the group's strengths (a leading R&D spender in the pharmaceutical industry with fifteen +CHF 1 billion blockbusters, etc.) and weaknesses (playing catch-up in the race for a share of the Obesity pie, etc.).

1. Overview

Presentation

Segments

SWOT

2. Corporate Strategies and Recent Events

3. Financial Indicators

4. Statistical Appendix

5. Glossary